热门资讯> 正文
MacroGenics扩大了与Sagard的ZYNYZ特许权使用费协议，预付6000万美元
2026-05-04 20:50
- MacroGenics (NASDAQ: MGNX) on Monday said it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners tied to global sales of its drug ZYNYZ.
- MacroGenics said it will receive $60 million upfront and could get up to $20 million in additional sales-based milestone payments in 2026 under the amended agreement.
- The deal grants Sagard a capped royalty interest in future global net sales of ZYNYZ, with rights reverting to MacroGenics once Sagard receives up to 1.7 times its investment by September 2032, or 2.0 times thereafter.
- ZYNYZ, a PD-1 inhibitor, was originally developed by MacroGenics and licensed to Incyte Corporation under a global collaboration agreement.
- Source: Press Release
More on MacroGenics
- MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
- MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- MacroGenics gains removal of FDA partial hold on lead program
- Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant
- Seeking Alpha’s Quant Rating on MacroGenics
推荐文章
港股周报 | 科指再跌破5000点！腾讯创近一年新低！马化腾表示上了AI的船后发现“漏水了”
一周财经日历 | 英伟达、沃尔玛、百度等下周齐放榜！新主席沃什上任后首份美联储会议纪要将出炉
美股机会日报｜通胀压力爆表+美拒绝伊朗停战方案，三大期指齐跌，油价一度飙涨3%；“木头姐”最新持仓出炉！再度减持特斯拉、押注太空概念
一周IPO | 中签即“吃肉”！乐动机器人、剂泰科技上市首日均涨超120%；翼菲科技孖展认购近1.49万倍，成港股新“超购王”
上市首日大涨68%！“英伟达挑战者”Cerebras创下2019年来美国科技公司最大IPO记录！（附投资分析）
华盛早报 | 特朗普持仓大曝光！大额买入英伟达、苹果；SpaceX招股说明书据悉最快下周披露！
特朗普第一季度进行3,642笔股票交易，打破数十年保密信托惯例
时隔九年再访华！特朗普携最强商业天团随行，美股半导体、存储、航空等七大板块或迎来利好
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
